← back to search

Matthew J. Bott

Milken Institute · US
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Lung Cancer Diagnosis and Treatment, Lung Cancer Treatments and Mutations, Esophageal Cancer Research and Treatment, and Cancer Genomics and Diagnostics.
h-index
36
citations
6,547
works
248
NIH funding
primary concept
Medicine
email

Recent publications

A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy
Cell 2026cited by 1position: middledoi
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
JAMA Oncology 2025cited by 23position: middledoi
Ageing limits stemness and tumorigenesis by reprogramming iron homeostasis
Nature 2024cited by 57position: middledoi
High-risk features associated with recurrence in stage I lung adenocarcinoma
Journal of Thoracic and Cardiovascular Surgery 2024cited by 37position: middledoi
The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer
The Annals of Thoracic Surgery 2024cited by 34position: middledoi
A Real-World Assessment of Stage I Lung Cancer Through Electronic Nose Technology
Journal of Thoracic Oncology 2024cited by 22position: middledoi
The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non–small cell lung cancer
Journal of Thoracic and Cardiovascular Surgery 2023cited by 69position: middledoi
Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer
Clinical Cancer Research 2022cited by 53position: middledoi
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
Nature 2021cited by 534position: middledoi
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer
Cancer Cell 2021cited by 423position: middledoi
Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma
British Journal of Anaesthesia 2021cited by 55position: middledoi
Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
Nature 2021cited by 13position: middledoi
Signatures of plasticity and immunosuppression in a single-cell atlas of human small cell lung cancer.
Journal of Clinical Oncology 2021cited by 5position: middledoi
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
Cell 2020cited by 584position: middledoi
A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma
JAMA Surgery 2020cited by 115position: middledoi
Single cell profiling reveals novel tumor and myeloid subpopulations in small cell lung cancer
bioRxiv (Cold Spring Harbor Laboratory) 2020cited by 8position: middledoi
NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
Science 2018cited by 433position: middledoi
Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancer
Journal of Thoracic and Cardiovascular Surgery 2018cited by 296position: firstdoi
Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: A Propensity Score–Matched Analysis
Journal of Thoracic Oncology 2018cited by 280position: middledoi
Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations
Journal of Thoracic Oncology 2013cited by 90position: middledoi
New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment
Clinical Cancer Research 2012cited by 88position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Prasad S. Adusumilli · Kettering University5 papers (2018–2024)David R. Jones · Concepts to Systems (United States)5 papers (2018–2024)Valerie W. Rusch · Cornell University4 papers (2013–2024)James M. Isbell · Memorial Sloan Kettering Cancer Center4 papers (2018–2024)Jamie E. Chaft · Faculty of 1000 (United States)4 papers (2018–2024)Charles M. Rudin · New York Proton Center3 papers (2018–2022)Kay See Tan · Cardiff University3 papers (2018–2024)Gaetano Rocco · Memorial Sloan Kettering Cancer Center3 papers (2021–2024)Bernard J. Park · Memorial Sloan Kettering Cancer Center3 papers (2018–2024)Elizabeth G. Dunne · Kettering University2 papers (2024–2024)James Huang · National University Health System2 papers (2024–2024)William D. Travis · Memorial Sloan Kettering Cancer Center2 papers (2018–2024)Marc Ladanyi · Center for Cancer Research2 papers (2012–2013)Jonathan Spicer · McGill University Health Centre2 papers (2023–2024)Patrick M. Forde · Johns Hopkins University2 papers (2018–2024)Natasha Rekhtman · Kettering University2 papers (2018–2024)Cameron N. Fick · Kettering University2 papers (2024–2024)Lee M. Krug · AstraZeneca (Switzerland)2 papers (2012–2013)Robert McMillan · Houston Methodist2 papers (2012–2013)Jacklynn V. Egger · Kettering University2 papers (2021–2022)